The use of herbal remedies in the prevention and treatment of pathology of the respiratory tract

Respiratory diseases are a widespread group of pathological processes that affect people of different ages. Inflammatory changes of various etiologies on the surface of the respiratory epithelium are accompanied by a violation of mucociliary clearance, and therefore the rate of evacuation of the secret decreases, its production increases, and the rheological properties of the mucin change. Significant accumulation of thick mucus is a clinical feature of many respiratory diseases, including acute rhinosinusitis. Appointment to patients with pathology of the respiratory system of drugs that affect the evacuation, properties and production of mucus, is pathogenetically justified. Phytopreparations GeloMirtol® and GeloMirtol® forte are effective in treating patients with rhinosinusitis of various ages, including children from 6 and 10, respectively. The active component of these drugs - Myrtle standardized - distillate eucalyptus oil (main ingredient - 66% of the total), myrtle, sweet orange and lemon, has a complex mechanism of action, has an expectorant, anti-inflammatory, bacteriostatic effect, helps clean the respiratory tract and restore normal mucous function shell. GeloMirtol® and GeloMirtol® forte simultaneously affect several parts of the development of the pathological process, increasing the results of complex treatment of respiratory diseases.

1. Fedyukovich N.I. Human anatomy and physiology. Rostov on/D: Phoenix, 2003. 357 p. (In Russ).

2. Piskunov G.Z., Piskunov S.Z. Inflammation of the mucous membrane. M.: Kolos, 2008:2-3. (In Russ).

3. Chikina S.Yu., Belevsky A.S. Mucociliary clearance in health and disease. Prnkticheskaya Pulmonologia. 2012;1(44):2-5. (In Russ).

4. Shakhova E.G. Acute bacterial rhinosinusitis (questions and answers). 2016:4-6. (In Russ).

5. . Amelina E.L. et al. Mucoactive therapy. Under the editorship of Chuchalin A.G., Belevsky A.S. M.: Atmosphere, 2006. 128 p. (In Russ).

6. Shartanova N.V. Mucolytics in clinical practice. Consilium Medicum. 2009;11:93-95. (In Russ).

7. Avdeev S.N. New opportunities for modern mucoactive agents for the treatment of patients with chronic obstructive pulmonary disease. Pulmonologia. 2014;2:100-108. (In Russ).

8. Revai K., Dobbs L.A., Nair S., Patel J.A., Grady JJ., Chonmaitree T. Incidence of acute otitis media and sinusitis complicating upper respiratory tract infection: the effect of age. Pediatrics. 2007;119:408-412.

9. Lopatin A.S., Svistushkin V.M. Acute rhinosinusitis: etiology, pathogenesis, diagnosis and treatment guidelines. Klinicheskie Rekomendatsii. 2009:12. (In Russ).

10. Fokkens WJ. et al. EPOS 2012: европейский позиционный документ по риносинуситу и полипам носа 2012. Резюме для оториноларингологов. Ринология. 2012;50(1):1-12.

11. Clinical guidelines CG 313 Acute sinusitis. http//glav-otolar.ru/klinicheskie-rekomendaczii/. (In Russ).

12. Lai Y., Dilidauer D., Chen B., Xu G., Shi J., Lee RJ. et al. In vitro studies of a distillate of rectified essential oils on sinonasal components of mucociliary clearance. American journal of rhinology & allergy. 2014;28(3):244-248.

13. Шаллер М. Препарат ГелоМиртол® форте «Поль Боскамп» ГМБХ, ФРГ. Рецепт. 2008;1(57):107-108.

14. Han D., Wang N. & Zhang L. The effect of myrtol standardized on human nasal ciliary beat frequency and mucociliary transport time. American journal of rhinology & allergy. 2009;23(6):610-614.

15. Grassmann J., Hipelli S., Dornisch K., Rohnert U., Beuscher N., Elstner E.F. Antioxidant Properties of Essential Oils. Arzneim.-Forsch. Drug Res. 2000;50(I):135-139.

16. Hipelli S., Grassman J., Dornisch K., Rohnert U., Elstner E.F. Freie Radikale in Pathogenese und Therapie von entzundlichen Erkrankungen des Bronchialsystems In: Meister R., Entzundliche Erkrankungen des Bronchialsystems, Springer Verlag. Berlin Auflage. 2000;1:1-25.

17. Beuscher N., Kietzmann M., Bien E., Champeroux P. Interference of Myrtol standardized with inflammatory and allergic mediators. Arzneim-Forsch. Drug Res. 1998;48(I):985-989.

18. Zimmermann Th., Seiberling M., Thomann P., Karabelnik D. Untersuchungen zur relative Bioverfugbarkeit und zur Pharmakokinetik von Myrtol standardisiert. Arzneim.-Forsch. Drug Res. 1995;45(II):1198-1201.

19. Federspil P., Wulkow R., Zimmermann T. Effects of standardized Myrtol in therapy of acute sinusitis-results of a double-blind, randomized multicenter study compared with placebo. Laryngo-rhino-otologie. 1997;76(1):23-27.

20. Ryazantsev S.V. Modern methods of therapy for acute and chronic sinusitis. Proceedings of the 1st Rus. Symposium on GeloMyrtol. M.; St. Petersburg, 1996:26-27. (In Russ).

21. Ryazantsev S.V. Secretolytic and secretomotor therapy for acute and chronic sinusitis. Novosti Otorinolaringologii i Logopatologii. 1998;4(16):90-92. (In Russ).